United States - English - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 10 mg - i. vasospastic angina nifedipine is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by st segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. in those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. nifedipine may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or when angina is refractory to nitrates and/or adequate doses of beta blockers. ii. chronic stable angina (classical effort-associated angina) nifedipine is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 30 mg - concomitant administration with strong p450 inducers, such as rifampin, are contraindicated since the efficacy of nifedipine tablets could be significantly reduced. (see precautions: drug interactions.) nifedipine must not be used in cases of cardiogenic shock. nifedipine is contraindicated in patients with a known hypersensitivity to any component of the tablet.

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 60 mg - concomitant administration with strong p450 inducers, such as rifampin, are contraindicated since the efficacy of nifedipine tablets could be significantly reduced. (see precautions: drug interactions.) nifedipine must not be used in cases of cardiogenic shock. known hypersensitivity to nifedipine.

United States - English - NLM (National Library of Medicine)

stat rx usa llc - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 10 mg - i. vasospastic angina : nifedipine is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by st segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. in those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. nifedipine may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or when angina is refractory to nitrates and/or adequate doses of beta blockers. ll. chronic stable angina (classical effort-associated angina) : nifedipine is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm i

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - nifedipine 20mg (plus 10% overage) - modified release tablet - 20 mg - active: nifedipine 20mg (plus 10% overage) excipient: cellulose acetate hypromellose   iron oxide red macrogol 3350 magnesium stearate opacode black s-1-17823 opadry pink oy-s-24914 polyethylene oxide sodium chloride - treatment of coronary heart disease

United States - English - NLM (National Library of Medicine)

tya pharmaceuticals - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 30 mg - nifedipine extended-release tablets are indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents. concomitant administration with strong p450 inducers, such as rifampin, are contraindicated since the efficacy of nifedipine tablets could be significantly reduced. (see .) precautions: drug interactions nifedipine must not be used in cases of cardiogenic shock. nifedipine extended-release tablets are contraindicated in patients with a known hypersensitivity to any component of the tablet.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 20 mg - nifedipine capsules, usp are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by st segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. in those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. nifedipine may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or when angina is refractory to nitrates and/or adequate doses of beta blockers. nifedipine capsules, usp are indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers an

United States - English - NLM (National Library of Medicine)

a-s medication solutions - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 30 mg - nifedipine extended-release tablets are indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents. concomitant administration with strong p450 inducers, such as rifampin, are contraindicated since the efficacy of nifedipine tablets could be significantly reduced. (see precautions, drug interactions .)  nifedipine must not be used in cases of cardiogenic shock. nifedipine is contraindicated in patients with a known hypersensitivity to any component of the tablet.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 60 mg - nifedipine extended-release tablets are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by st segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. in those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. nifedipine extended-release tablets may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers. - (classical effort-associated angina) (classical effort-associated angina

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - nifedipine (unii: i9zf7l6g2l) (nifedipine - unii:i9zf7l6g2l) - nifedipine 30 mg - adalat® cc is an extended release tablet dosage form of the calcium channel blocker nifedipine. nifedipine is 3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-dimethyl ester, c17 h18 n2 o6 , and has the structural formula: nifedipine is a yellow crystalline substance, practically insoluble in water but soluble in ethanol. it has a molecular weight of 346.3. adalat cc tablets consist of an external coat and an internal core. both contain nifedipine, the coat as a slow release formulation and the core as a fast release formulation. adalat cc tablets contain either 30, 60, or 90 mg of nifedipine for once-a-day oral administration. inert ingredients in the formulation are: hydroxypropylcellulose, lactose, corn starch, crospovidone, microcrystalline cellulose, silicon dioxide, and magnesium stearate. the inert ingredients in the film coating are: hypromellose, polyethylene glycol, ferric oxide, and titanium dioxide.